INSECTICIDES (INDIA) LTD. - 532851 - Intimation Of Receipt Of Patent (NOVEL MITICIDAL BENZYLAMIDES)
This is to inform you that the Patent Office has granted the Patent for an invention entitled NOVEL MITICIDAL BENZYLAMIDES for the term of 20 years from 18th day of July, 2016 (date of filing). INSECTICIDES (INDIA) LTD. - 532851 - Intimation Of Receipt Of PATENT (NOVEL DITHIOLANE COMPOUND OR A SALT OR AN N-OXIDE AND USE THEREOF)
This is to inform you that the Patent Office has granted the Patent for an invention to the Company and its Joint Venture named OAT Agrio Co. Ltd entitled NOVEL DITHIOLANE COMPOUND OR A SALT OR AN N-OXIDE AND USE THEREOF for the term of 20 years from 14th day of March, 2018 (date of filing). INSECTICIDES (INDIA) LTD. - 532851 - Intimation Of Receipt Of Patent (Novel Granules And Its Pesticidal Compositions)
This is to inform you that the Patent Office has granted the Patent for an invention entitled Novel Granules And its Pesticidal Compositions for the term of 20 years from 11th day of July, 2019 (date of filing). INSECTICIDES (INDIA) LTD. - 532851 - Compliance Certificate
Compliance Certificate Under Regulation 7(3) of SEBI (LODR) Regulations, 2015 INSECTICIDES (INDIA) LTD. - 532851 - Closure of Trading Window
It is informed that the ''trading window'' for dealing in securities of Insecticides (India) limited shall remain closed from April 01, 2022 till the end of 48 hours after declaration of financial results for the financial year ended on March 31, 2022 are made public. INSECTICIDES (INDIA) LTD. - 532851 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors/Analyst Plant Visit/Meeting under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Q3FY22 Quarterly Result Announced for Insecticides (India) Ltd.
Insecticides (India) announced Q3FY22 results: Q3FY22 vs Q3FY21: Revenue from Operations has marginally grown from Rs.2991.74 Mn in Q3 FY21 to Rs.3137.78 Mn in Q3 FY22 mainly due to better product mix. The EBITDA has increased by 23.27% from Rs.150.73 Mn in Q3 FY21 to Rs.185.81 Mn in Q3 FY22 mainly due to efficient inventory management. EBITDA margins has increased to 5.92% in Q3 FY22 from 5.04% in Q3 FY21. Net profit has increased by 32.83% from Rs.59.82 Mn in Q3 FY21 to Rs.79.46 in Q3 FY22 PAT margins have increased to 2.63% in Q3 FY22 from 2.06% in Q3 FY21. The Exports have increased to 15% in Q3 FY22 from 5% in Q3 FY21. 9MFY22 vs 9MFY21: Revenue from Operation has recorded a growth of 5.27% from Rs.11,646.21 Mn in 9M FY21 to Rs.12,259.78 Mn in 9M FY22 mainly driven by better product mix, focusing on Maharatna Products. The EBITDA has increased by 11.30% from Rs.1220.29 Mn in 9M FY21 to Rs.1358.23 Mn in 9M FY22 and a gain in the EBITDA margins from 10.48% in 9M FY21 to 11.08% in 9M FY22. Net profit stood at Rs.848.80 Mn in 9M FY22, compared to Rs.721.17 Mn in 9M FY21 recorded a growth of 17.70% The Exports have increased to 8% in 9M FY22 from 4% in 9M FY21 Commenting on the performance, Mr. Rajesh Aggarwal, Managing Director, said: “The third quarter has been relatively subdued quarter for the entire agro-chemical industry, due to the building threat of Covid-19, unseasonal rains in parts of our country and damp market conditions. The scaling up of new products already launched in previous quarters has been hampered by barriers in working with the farmers on the grass root level, due to the looming third wave threat of Omicron variant of Covid-19. However, IIL has delivered a consistent performance in terms of Revenue and Sales volume in Q3 FY22, focussing on exports as per its growth plan for the current fiscal year. The Company has recorded revenue from operations of Rs.3137.78 Mn in Q3 FY22, and Rs.12259.78 Mn on a 9M basis, representing a growth of 5.27% on a 9M basis. Revenue growth was driven by better product mix focusing on Maharatna Products. The Maharatna category of branded products grew to 45.94% from Rs.747.23 Mn in Q3 FY21 to Rs.839.91 Mn in Q3 FY22. The exports grew by a whopping 224.17% and institutional sales grew by 6.10% on a quarterly basis. We are happy to state that we have achieved an export sale of Rs 1036.23 MN on a 9M basis in FY22 vs our total export turnover of Rs 610 MN on a full year basis of FY21. The Company delivered EBITDA of Rs.185.81 Mn in Q3 FY22, with margins of 5.92%. Net profit for the quarter was Rs.79.46 Mn, with margins of 2.63%. We are also in course of adding new molecules and products to our products portfolio, some of which are to replace off-patented products. The company is also working on new products to replace any of its current products which have a possibility of a ban in future. We expect to launch at least 2 new products in Q4 of FY22, in addition to new launches already done during the fiscal year. The company also expects to derive benefits from its backward integration capabilities at Dahej, to reduce dependency on Chinese raw materials in the long run. Currently, IIL is trying to streamline production by maintaining higher levels of inventory and using judicious purchase strategies. With the government’s focus on Bio Chemicals and increasing Exports, in tune with its MakeIn-India movement, IIL plans to capitalize on this opportunity on the back of its backward integration initiatives and its strong research & development program. The company foresees a huge potential for its products in the international market and therefore, we were able to surpass our export target, for FY22, of achieving more than Rs.1000 Mn in 9M ended 31st December, 2021 itself. On a long-term basis, the management foresees exports contributing to at-least 20% of the top line on an overall basis. This target is planned to be achieved by manufacturing newly identified molecules, especially for the international market and advent into new geographies like East & West Europe, Africa, & CIS & NAFTA markets particularly Canada Thus, IIL has been constantly delivering an intrinsic growth by strengthening its capacities & generating new revenues to replace revenues of banned products. The Management remains committed to continue its efforts to scale up sustainable revenues and take all other strategic measures so as to increase the long-term value for all its stakeholders.” Result PDF INSECTICIDES (INDIA) LTD. - 532851 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the Q3FY2022 Earning Presentation and Press release on the Third Quarter and Nine months ended Financial Results of the Company. INSECTICIDES (INDIA) LTD. - 532851 - Results For The Quarter Ended December 31, 2021.
The Board of Directors at the meeting held today, i.e February 10, 2022 inter alia considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company, for the Quarter and nine months ended December 31, 2021 INSECTICIDES (INDIA) LTD. - 532851 - Board Meeting Outcome for Outcome Of The Board Meeting
The Board of Directors at the meeting held today, i.e February 10, 2022 inter alia considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company, for the Quarter and nine months ended December 31, 2021